Santiago Vázquez is a Full Professor in Organic and Medicinal Chemistry in the Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences o the University of Barcelona (UB). He is also a founder member of the Institute of Biomedicine of the Universitat de Barcelona (IBUB). He has over 25 years of experience working on organic and medicinal chemistry, with focus on the synthesis of new compounds with potential biological activity. After his PhD in the UB (1996, PhD Extraordinary Prize of the UB), he spent two years (1998-2000) at the University College London working as a Marie Curie Research Fellow of the European Union within the group of Prof. William B. Motherwell. He returned to Barcelona in 2000 as Assistant Professor, he was “Investigador Ramón y Cajal” for four years and was later promoted to Associate Professor in 2005. So far he has supervised 13 PhD Thesis, and several MSc Research projects.
After working several years in pure organic chemistry -novel synthetic methodology, chemistry of polycyclic hydrocarbons-, more recently his research has focused on the synthesis of novel channel blockers -human NMDA and P2X7, M2 channel of the influenza virus- and novel enzyme inhibitors, including 11b-HSD1 inhibitors and soluble epoxide hydrolase inhibitors. For his medicinal chemistry programs he has established successful collaborations with several biological and computational groups.
He has participated as PI in several research projects from public funding agencies and in several research contracts with Spanish and international chemical and pharmaceutical companies. He is co-inventor in several patent and patent applications both in new chemical entities with biological activity and in the new processes for the manufacturing of generic active pharmaceutical ingredients (API).
His teaching activities have been mainly focused on topics related to Medicinal Chemistry and Synthesis of Drugs, being the coauthor of some textbooks on these topics.
Our research revolves around the design, synthesis and characterization of new polycyclic compounds of therapeutic interest. The biological activity of these compounds is evaluated by several collaborators with expertise in each specific biological target (see “research” and “collaborations”).
Within our group, a particular emphasis is placed on providing our PhD students with outstanding training not only in experimental research but also in teaching, scientific writing, communication and social skills, etc. Four former PhD students were awarded the “Extraordinary Price for PhD of the Universitat de Barcelona” and two of them were subsequently funded by the prestigious “Marie Curie Fellowship”. We are proud of the prominent positions that the former members of our group currently hold in private chemical and pharmaceutical companies.
Dr. Eugènia Pujol Assistant Professor
Dr. Andreea L. Turcu Assistant Professor
Dr. Sandra Codony Assistant Professor
Dr. Carla Barbaraci Postdoctoral Researcher
Beatrice Jora PhD Student
Celia Escriche PhD Student
Javier Sánchez PhD Student
In memoriam Dr. Oscar Lozano Assistant Professor
Dr. Eugènia Pujol
is an Assistant Professor at Vázquez’s group. As an undergraduate, after finishing her Degree in Pharmacy in July 2015, she gained work experience in the R&D Department of Almirall S.L. thanks to a four-month trainee program in its Medicinal Chemistry Department. Afterwards, she completed an official postgraduate study in pharmaceutical sciences, in which she carried out synthetic work by joining Vázquez’s laboratory. In October 2016 she enrolled the PhD program and she has recently (2021) received her PhD by the University of Barcelona. Her project consisted of the design and synthesis of urea-based compounds with a broad range of therapeutic applications and, especially, the discovery of novel soluble epoxide hydrolase inhibitors as potential treatments for neurodegenerative diseases. As part of her PhD, she has also done a five-month research placement within Prof. Knapp’s research group (Institute of Pharmaceutical Chemistry, Goethe-University, Frankfurt am Main), where she gained insight into the rational design of selective inhibitors as chemical probes. Finally, she has complemented her scientific background with business knowledge, thanks to the participation in several entrepreneurship programs and courses in intellectual property.
Dr. Andreea L. Turcu
is an Assistant Professor. She joined our group in 2013 as an undergraduated, doing synthetic work in organic and medicinal chemistry. After finishing her degree in Pharmacy (University of Barcelona, 2015), she started her PhD in 2016 and successfully completed it in 2021, under the supervision of Prof. Santiago Vázquez and Prof. David Soto (Faculty of Medicine, UB) working in a multidisciplinary project. She is currently working within the group in the design, synthesis and biological evaluation of novel compounds with activity in targets of interest for the treatment of Alzheimer’s disease, influenza virus and coronavirus. As part of her PhD, she had the opportunity to be part of Dr. Raphael Rodriguez’s group (Institut Curie, Paris), working for 3 months on the synthesis and pharmacological evaluation of DMT1 blockers, as a new perspective for cancer therapy. Furthermore, she collaborated with several pharmaceutical companies being in charge of the identification, determination and synthesis of impurities in drugs. Therefore, she has expertise in a broad range of experimental topics, encompassing organic synthesis, electrophysiology (Patch Clamp Whole Cells) and IC50 determination in cell cultures.
Dr. Sandra Codony
Dr. Sandra Codony is an Assistant Professor who has joined Dr. Carles Galdeano’s and Dr. Diego Muñoz-Torrero’s groups in collaboration with the Vall d’Hebron Institute of Oncology (VHIO). After obtaining her degree in Pharmacy at the Faculty of Pharmacy and Food Sciences at University of Barcelona in 2015, she started her PhD studies in Medicinal Chemistry under the supervision of Dr. Santiago Vázquez (2015 – 2020), working on a multidisciplinary project focused on the design, synthesis and evaluation of new soluble epoxide hydrolase (sEH) inhibitors with potential biological activity, and their applications in different inflammatory diseases. As a part of her PhD, she spent three months conducting research at the Institute of Cancer Research in London under the supervision of Dr. Swen Hoelder.
Dr. Carla Barbaraci
is a Postdoctoral researcher who recently joined Vázquez’s group. After finishing her degree in Pharmaceutical Chemistry and Technology at the University of Catania in 2015, she obtained a second-level Professional Master’s Program in Drug Design and Development at the University of Pavia. During this period, she did also a 6 months Erasmus+ placement at the University of Barcelona within the Dr. Muñoz-Torrero’s research group. Afterwards, she completed an official postgraduate study in pharmaceutical sciences, in which she carried out synthetic work under the supervision of Prof. Pelayo Camps at the University of Barcelona. In 2018 she started and recently received (June 2021) her PhD in Pharmaceutical Biotechnology at the University of Catania under the supervision of Prof. Agostino Marrazzo. Her project involved the design, synthesis and biological evaluation of Sigma-HDAC hybrids as potential therapeutic treatment for uveal melanoma. As part of her PhD, she spent 6 month within the group of Prof. Pedro Merino at the University of Zaragoza and 6 month working on pharmacological evaluation of small molecules on tumor cells in a target discovery biotech company.
is graduated in Chemistry and with a Master Degree in Organic Chemistry from the University of Barcelona. With an extended previous background in a chemical company, she decided to grow up and widen her knowledge in medical chemistry and started her PhD in our group in January 2019. The topic of her PhD is the discovery and optimization of new routes of synthesis of active principal ingredients in collaboration with pharma industry.
is graduated in Chemistry and with a Master’s degree in Organic Chemistry from the University of Barcelona. As an undergraduate student, she worked in the research group of Stereoselective Synthesis of Natural Products at the University of Barcelona, working under the supervision of Dr. Fèlix Urpí. In February 2022, she joined the group of Dr. Santiago Vázquez as a master’s student, where she worked in the synthesis of amines with potential biological interest. Afterward, she did a two-month placement at the Center for Research in Biological Chemistry and Molecular Materials (CiQUS) at the University of Santiago de Compostela in Dr. Eddy Sotelo’s research group, where she worked in the synthesis and evaluation of selective Cannabinoid CB2 receptor agonists for the treatment of multiple sclerosis. In September 2022 she started her PhD under the supervision of Prof. Santiago Vázquez.
is graduated in Chemistry from the Autonomous University of Madrid with a master in Drug Discovery. After graduation, he joined Spanish National Cancer Research Center (CNIO, Madrid), where he worked in the Medicinal Chemistry section as a synthetic chemist, gaining experience in the early stages of the drug discovery process. He collabored in the synthesis and optimization of compounds, either classical small-molecule inhibitors or protein degraders.
He started his PhD. under the supervision of Dr. Diego Muñoz-Torrero and Dr. Santiago Vázquez in September 2022. The topic of his thesis will focus on the rational design, synthesis and evaluation of novel drug candidates with innovative mechanisms of action for the treatment of neurodegenerative diseases and neuropathic pain.
Dr. Oscar Lozano
Óscar studied Biology (BSc 1997) and Pharmacy (BSc 2002) at the University of Barcelona. Later on, he carried out a PhD in Synthetic Organic Chemistry under the supervision of Prof. J. Bosch, M. Amat and Dr. C. Escolano regarding total synthesis of natural products (UB, 2007). After a short postdoctoral stay in the group of Prof. J. Cossy (ESPCI, Paris, 2007) he worked in the group of Prof. V. Gouverneur (University of Oxford) for more than five years. After returning to Barcelona in 2013, he worked in different pharmaceutical and chemical companies. In July 2017, he joined BioPharma Synergies as a senior researcher, a position that he shared with a part-time Assistant Professor within our group until his untimely death in November 2021. We will always remember him as an outstanding chemist, an excellent mentor, and a wonderful friend.
P2X7 receptor antagonists are of interest in inflammatory and neurodegenerative diseases. In collaboration with Prof. Yong-Chul Kim (Gwangju Institute of…
This is a more recent topic within our group. We have recently discovered that the lipophilic cavity of the sEH…
Codony, S.; Pont, C.; Griñán-Ferré, C.; Di Pede-Mattatelli, A.; Calvó-Tusell, C.; Feixas, F.; Osuna, S.; Jarné-Ferrer, J.; Naldi, M.; Bartolini,…
Rodríguez-Arévalo S, Pujol E, Abás S, Galdeano C, Escolano C, Vázquez S. Molecules. 2021, 26, 906. doi: 10.3390/molecules26040906. AR-15512 (formerly…
Codony S, Calvó-Tusell C, Valverde E, Osuna S, Morisseau C, Loza MI, Brea J, Pérez C, Rodríguez-Franco MI, Pizarro-Delgado J,…
I have been involved in more than 40 research projects, funded either from public calls or from private chemical and pharmaceutical companies. It follows a list of the research from the last six years (2015-2021).
Participation in funded R+D+I projects from public calls
Exploración de nuevas dianas y estrategias multidiana para el diseño de compuestos contra enfermedades infecciosas y prevalentes Ministerio de Economia y Competitividad SAF2014-57094-R, 180.000,00 € 01/01/2015 – 31/12/2017
Drugs for inflammatory & cardiovascular disorders. Fase 1. CI15-00020. Fundació Caixa de Pensions ‘La Caixa’6.000,00 € 01/09/2015 – 31/01/2016
Drugs for inflammatory & cardiovascular disorders Fase 2. CI15-00020. Fundació Caixa de Pensions ‘La Caixa’ 50.000,00 € 01/02/2016 – 31/01/2017
Efficacy and safety assessment of novel soluble epoxide hydrolase inhibitors for the prevention and treatment of acute pancreatitis (sEHIAP) Proof of Concept Grant – European Institute of Innovation & Technology – EIT Health HS-2016-SPAIN-04, 25.000,00 € 01/02/2016 – 30/09/2017
Synthesis of compounds with innovative mechanisms against neurodegenerative diseases Ministerio de Economia y Competitividad SAF2017-82771-R, 121.000,00 € 01/01/2018 – 31/12/2020
Therapeutic and prophylactic effects of soluble Epoxide Hydrolase Inhibitors (sEHI) in acute pancreatitis (AP) and in Endoscopic Retrograde Cholangiopancreatography (ERCP)-induced AP (F2I-FVal-2017-015). Fundació Bosch i Gimpera de la Universitat de Barcelona, 25.000,00 € 18/12/2017 – 17/12/2018
New HRI activators for the treatment of type 2 Diabetes Mellitus. CI18-00006. Fundació Caixa de Pensions ‘La Caixa’, 100.000,00 € 03/12/2018 – 02/03/2020
Discovery of innovative drugs against viral respiratory infections (MARATO TV3 201832-30) Fundació La Marató de TV3 199.175,00 € 01/06/2019 – 31/05/2022
Channel block and gating of NMDA receptors National Institutes of Health (NIH) (subaward of a NIH Project of Prof. Jon W. Johnson, University of Pittsburgh, USA) 2R01GM128195-26A1, 71.376,00 USD (64.625,83 €) 01/01/2019 – 31/12/2022
A new pan-coronavirus therapeutic concept to address present and future infections: targeted degradation of the conserved 3CLpro Fundació La Marató de TV3, 300.000,00 €
01/09/2021 – 31/08/2023
Synthesis of compounds with innovative mechanisms against neurodenegerative diseases and neuropathic pain (InnoNeurox2) Ministerio de ciencia e innovación, 272.250,00 € 01/09/2021-31/08/2024
Tackling neuropathic pain with first-in-class dual agents. CI20-00147 (Caixaimpulse Validate) Fundació Caixa de Pensions ‘La Caixa’, 100.000,00 €
16/12/2020 – 15/03/2022
Ca2+-Dependent block by memantine and selective inhibition of overactive NMDA National Institutes of Health (NIH, USA), 187.580,00 USD 15/09/2020-31/05/2025
Participation in R+D+I Contracts of special importance with companies
Síntesi i Avaluació Farmacològica de noves molècules amb propietats antidiabètiques (SAFNAD) CIDQO 2012, S.L. & ACC1Ó UBAR 012688, 67.000,00 € 01/07/2014 – 30/06/2016
Consulting in organic chemistry Menadiona, S.L. FBG 310144, 17.563,00 € 01/01/2018 – 31/10/2019
Open Innovation Drug Discovery Program Eli Lilly and Company FBG 308988, 5.200,00 USD 01/12/2016 – 30/11/2017
Consulting in organic chemistry CIDQO 2012, S.L FBG308987, 82.616,73 € 01/06/2016 – 31/12/2017
Optimization of the route of synthesis of active pharmaceutical ingredients Biopharma Synergies (BPS), S.L FBG 309411 36.000,00 € 01/07/2017 – 14/01/2018
Optimization of the route of synthesis of active pharmaceutical ingredients Biopharma Synergies (BPS), S.L FBG 309658, 66.000,00 € 15/01/2018 – 31/12/2018
Synthesis of active pharmaceutical ingredients intermediates and intermediates Biopharma Synergies (BPS), S.L UBAR 18648, 36.000,00 € 01/01/2019 – 31/12/2021
In addition to our academic interests, one of the main aims of our group is to generate Intellectual Property stemming either from our research projects or from join research projects with several chemical and pharmaceutical companies.
Below there is a list of recent selected patent and patent applications by our group. Their titles give an idea of the wide range of topics of our group.
Bruce D. Hammock and Christophe Morisseau (University of California Davis, Davis, USA), Jon W. Johnson (University of Pittsburgh, USA), Yong-Chul Kim (Gwangju Institute of Science & Technology, Gwangju, South Korea), Antonios Kolocouris (University of Athens, Greece), Mabel Loza and José M. Brea (Universidad de Santiago de Compostela, Spain). Javier Luque (Universitat de Barcelona, Spain), Anna Moroni and Sabrina Gazzarrini (University of Milano, Italy), Lieve Naesens (KU Leuven, Leuven, Belgium), David Soto (Universitat de Barcelona, Spain), Francesc X. Sureda (Universitat Rovira i Virgili, Tarragona, Spain), Manuel Vázquez-Carrera (Universitat de Barcelona, Spain), Jun Wang (University of Arizona, Tucson, Arizona, USA), Scott P. Webster (University of Edinburgh, UK), Antonio Ferrer and Asia Fernández (Universidad Miguel Hernández, Elche, Spain), Christa Müller (Universität Bonn, Germany), Steven E. Mansoor (Oregon Health and Science University, Portland, USA), Annette Nicke (Ludwig-Maximilians-Universität, Munich, Germany), Maria Kurnikova (Carnegie Mellon University, Pittsburgh, USA), Jordi Llop (CIC biomaGUNE, San Sebastian, Guipuzcoa, Spain), Mercè Pàllas and Christian Griñán-Ferré (Universitat de Barcelona, Spain), Carles Galdeano and Xavier Barril (Universitat de Barcelona, Spain), Enrique J. Cobos (University of Granada, Spain), Coral Sanfeliu Pujol (Institut d’Investigacions Biomèdiques de Barcelona, Spain), Belen Pérez (Autonomous University of Barcelona), Emanuele Amata and Agostino Marrazzo (University of Catania, Italy), Francisco Ciruela (Universitat de Barcelona, Spain).
Prof. Dr. Santi Vázquez
firstname.lastname@example.org Laboratory of Medicinal Chemistry Faculty of Pharmacy and Food Sciences University of Barcelona & Institute of Biomedicine (IBUB) Tel. +34 934024533
ORCID: 0000-0002-9296-6026 Scopus Author ID: 57034307500 Researcher ID: R-3551-2016